Zhejiang Garden Biopharmaceutical Co., Ltd. (300401.SZ) manufactures and supplies vitamin D3, cholesterol, and related derivatives for applications in food additives, animal nutrition, human health products, and pharmaceuticals. Founded in 2000 and headquartered in Dongyang, Zhejiang Province, China, the company operates primarily in China with exports to Europe, North America, South America, and East Asia; it listed on the Shenzhen Stock Exchange's Growth Enterprise Market in 2014 and changed its name from Zhejiang Garden Bio-chemical High-tech Co., Ltd. in April 2023 to reflect its expanded biopharmaceutical focus. Core products include lanolin cholesterol; feed-grade vitamin D3 particles, oil, and resin; 25-hydroxyvitamin D3 in powder and progen forms; refined and anhydrous lanolin; lanolin alcohol; lanolin fatty acid; isopropyl lanolate; vitamin A and AD3 particles; cholecalciferol; compound nutrient fortifiers such as SDS, CO, and MO; wood oil and wool wax derivatives; low chroma pure fat; high acid fat; wood acid and alcohol biofuels; and Vitamin D3-based rodenticides; the company also produces chemical drugs and Chinese patent medicines, including Alendronate Sodium Tablets through its wholly-owned subsidiary Zhejiang Gelon Biochemical Co., Ltd. Recent developments encompass the selection of its subsidiary's Alendronate Sodium Tablets for China's 11th round of national centralized drug procurement in November 2025, enhancing pharmaceutical market share; commencement of a 6,000-ton annual vitamin A powder production project; strong 2025 financial performance with third-quarter revenue growth and improved net profit amid cost controls and rising lanolin output; sustained 30-40% domestic market share in vitamin D3; and strategic "one vertical, one horizontal" expansion, deepening the vitamin D3 chain while pursuing mergers in global vitamin markets; in 2018-2021, it relocated to the 771-acre Jinxi Science and Technology Park for advanced digital production compliant with environmental standards.